SCHEMBL2848262

SCHEMBL2848262

CCOC(=O)CNC(=O)Nc1nc2c(Cl)cccc2s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.59
GAA P10253 2/20 0.55
KMT2A Q03164 5/20 0.50
MAPK1 P28482 4/20 0.49
MMP3 P08254 1/20 0.49
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 3/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 4/20 0.47
ALDH1A1 P00352 4/20 0.47
LMNA P02545 3/20 0.47
HPGD P15428 2/20 0.47
PKM P14618 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
POLA1 P09884 1/20 0.47
ACP1 P24666 1/20 0.47
SENP7 Q9BQF6 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2793231 0.90 GAA (0.52) HTTGAAKMT2AMAPK1TSHR
SCHEMBL2788879 0.83 KMT2A (0.59) GAAKMT2AMAPK1TSHRNPSR1
SCHEMBL2789721 0.82 MAPK1 (0.72) HTTGAAKMT2AMAPK1MMP3
Potassium Ion SCHEMBL2790164 0.81 KMT2A (0.54) GAAKMT2AMAPK1TSHRNPSR1
SCHEMBL5731223 0.79 TRPV1 (0.57) HTTGAAKMT2ANPC1RAB9A
SCHEMBL2842399 0.79 MAPT (0.58) HTTGAAKMT2AMAPK1NPSR1
SCHEMBL2791913 0.79 PTPN1 (0.69) MAPK1NPC1RAB9ASMN1; SMN2SENP7
SCHEMBL30754208 0.76 DYRK1A (0.71) GAAKMT2AMAPK1TSHRNPSR1
SCHEMBL11714671 0.76 MAPT (0.60) GAAKMT2AMAPK1TSHRNPSR1
SCHEMBL3446775 0.76 GAA (0.49) HTTGAAKMT2AMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012481-B2 Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-04-21 US disclosed
US-9012481-B2 Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-04-21 US disclosed
US-20110319456-A1 BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-12-29 US disclosed
US-20110319456-A1 BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-12-29 US disclosed
WO-2010077068-A2 BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319456-A1 BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME HTT, PSEN1, PYGB HTT 1/4885GAA 17/4885KMT2A 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.